Histone Deacetylase Inhibitor ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 127 | Frontotemporal lobar degeneration | 5 |
127. Frontotemporal lobar degeneration
Clinical trials : 89 / Drugs : 104 - (DrugBank : 33) / Drug target genes : 40 - Drug target pathways : 117
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-001489-85-BE (EUCTR) | 05/03/2015 | 24/10/2014 | A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: FRM-0334 INN or Proposed INN: Histone Deacetylase Inhibitor Other descriptive name: EVP-0334 | FORUM Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | France;United States;Belgium;Netherlands;Italy;United Kingdom | ||
| 2 | EUCTR2014-001489-85-GB (EUCTR) | 23/02/2015 | 12/08/2014 | A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: FRM-0334 INN or Proposed INN: Histone Deacetylase Inhibitor Other descriptive name: EVP-0334 | FORUM Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | France;United States;Belgium;Netherlands;Italy;United Kingdom | ||
| 3 | EUCTR2014-001489-85-IT (EUCTR) | 22/12/2014 | 02/10/2014 | A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation MedDRA version: 17.0;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: FRM-0334 INN or Proposed INN: Histone Deacetylase Inhibitor Other descriptive name: EVP-0334 | FORUM Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | France;United States;Belgium;Netherlands;United Kingdom;Italy | ||
| 4 | EUCTR2014-001489-85-NL (EUCTR) | 19/12/2014 | 23/09/2014 | A study to investigate 2 doses of investigational drug on patients with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: FRM-0334 INN or Proposed INN: Histone Deacetylase Inhibitor Other descriptive name: EVP-0334 | FORUM Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | France;United States;Belgium;Netherlands;Italy;United Kingdom | ||
| 5 | NCT02149160 (ClinicalTrials.gov) | October 2014 | 20/5/2014 | Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation | A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation | Granulin Mutation | Drug: FRM-0334;Drug: Placebo | FORUM Pharmaceuticals Inc | NULL | Active, not recruiting | 21 Years | 75 Years | Both | 30 | Phase 2 | United States;Belgium;France;Italy;Netherlands;United Kingdom |